CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D003095: Collagen Diseases NIH

(Synonyms: Collagen Diseases)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (6)


Name (Synonyms) Correlation
drug220 COVID-19 infection Wiki 0.71
drug535 Hydroxychloroquine and Ivermectin Wiki 0.71
drug215 COVID-19 barrier box Wiki 0.71
drug534 Hydroxychloroquine and Azithromycin Wiki 0.50
drug239 Camostat Mesilate Wiki 0.35
drug505 Hydroxychloroquine Wiki 0.08

Correlated MeSH Terms (10)


Name (Synonyms) Correlation
D012216 Rheumatic Diseases NIH 1.00
D012213 Rheumatic Fever NIH 0.71
D001167 Arteritis NIH 0.50
D025241 Spondylarthritis NIH 0.50
D011111 Polymyalgia Rheumatica NIH 0.50
D013700 Giant Cell Arteritis NIH 0.50
D015535 Arthritis, Psoriatic NIH 0.41
D001327 Autoimmune Diseases NIH 0.41
D008180 Lupus Erythematosus, Systemic NIH 0.35
D001168 Arthritis NIH 0.27

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0012089 Arteritis HPO 0.50
HP:0002960 Autoimmunity HPO 0.41
HP:0002725 Systemic lupus erythematosus HPO 0.35
HP:0001369 Arthritis HPO 0.27

There are 2 clinical trials

Clinical Trials


1 COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.

NCT04335747 Rheumatoid Arthritis Psoriatic Arthritis Axial Spondyloarthritis Systemic Lupus Erythematosus Giant Cell Arteritis Other: COVID-19 infection
MeSH:Arthritis Arthritis, Psoriatic Rheumatic Diseases Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Collagen Diseases
HPO:Arteritis Arthritis Polyarticular arthritis Systemic lupus erythematosus

Primary Outcomes

Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease

Measure: Disease activity

Time: Last registration of disease activity in the medical journal before admission/inclusion

Secondary Outcomes

Description: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.

Measure: Immune modulating treatments

Time: Current immune modulating treatments at admission/inclusion

Description: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups

Measure: Biomarkers

Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1

2 Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases : a Retrospective Multicenter Observational Study

Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.

NCT04353609 Sars-CoV2 Chronic Inflammatory Rheumatism Autoimmune Diseases
MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases Autoimmune Diseases
HPO:Autoimmunity

Primary Outcomes

Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death

Time: From Baseline up to Day 21 after first symptoms of covid-19

Secondary Outcomes

Measure: Proportion of patients who die from a severe form of covid-19

Time: From Baseline up to Day 21 after first symptoms of covid-19

Measure: Proportion of patients who present an history of diabetes according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2)

Time: At the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Asthma according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Hypertension according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of cardiac disease according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of stroke according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of cancer according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)


HPO Nodes